Larotinib mesylate hydrate_product_DataBase

Bioactivity	Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1].
In Vivo	每日给 Larotinib mesylate hydrate 后，SD 大鼠无不良反应水平 (NOAEL) 为 10 mg/kg, 比格犬最低不良反应水平 (LOAEL) 为 5 mg/kg。最大耐受剂量 (MTDs) 在 SD 大鼠和比格犬中分别为 20 和 25 mg/kg[1]。Larotinib mesylate hydrate 显示出剂量依赖性的抗肿瘤结果，在肿瘤小鼠模型中，18 mg/kg 肿瘤抑制率超过 60% (数据未发表)[1]。
Name	Larotinib mesylate hydrate
CAS	2097129-93-4
Formula	C26H36ClFN4O11S2
Molar Mass	699.17
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.

PeptideDB